Double-immunofluorescence labeling indicates that cPLA 2 Is Expressed in EAE Lesions
We first assessed the expression of cPLA 2 in the spinal both CD4 ϩ T cells and Mac-1 ϩ macrophages express cPLA 2 in these immune cell infiltrates (Figures 2B and cord of C57BL/6 mice with EAE. If PLA 2 plays a role in MOG-induced EAE in C57BL/6 mice, it has to be medi-2C). The number of CD4 ϩ T cells expressing cPLA 2 in lesions remains the same throughout the different cliniated mainly by cPLA 2 , because this strain lacks the major form of sPLA 2 . Increased expression of cPLA 2 was cal grades ( Figure 2C ), whereas the number of macrophages expressing cPLA 2 in EAE lesions increases with observed by immunohistochemistry at the site of EAE lesions. This increased expression was assessed in cerdisease severity (Figure 2 ). Collectively, these data indicate that cPLA 2 is expressed in the CNS very early during vical, thoracic, and lumbar regions of the spinal cord of mice at clinical grades of 1-5 during their first paralytic the clinical course of EAE, may contribute to the influx of inflammatory cells into the CNS, and may underlie the attack. The immunohistochemical labeling for cPLA 2 occurred in both endothelial cells and immune cells in the pathological and clinical changes characteristic of EAE. CNS inflammatory infiltrates ( Figure 1A) . A high percentage of cPLA 2 ϩ endothelial cells were seen in the spinal Blocking cPLA 2 Prevents Onset and Progression of EAE cord early in the course of the disease, ranging from about 60%-85% in grades 1-3 and decreased to about To assess if cPLA 2 is important for the onset of EAE, we blocked it using an AA analog, arachidonyl trifluromethyl 20% at clinical grades 4 and 5 ( Figure 1B) . The percentage of cPLA 2 ϩ immune cells in EAE lesions remained at ketone (AACOCF 3 ), which is a potent and selective inhib-of the disease was also markedly reduced in the treated mice. Control animals reached an average maximum clinical score of about 3 at day 15, while the 2 mM and 4 mM treated groups reached scores of 1.3 and 0.4, respectively (Figure 3) . When only the animals that got EAE symptoms in the 2 mM and 4 mM treated groups were considered, they reached a mean maximal grade of 2.25 and 1.5, respectively, on day 15, compared to a 2.9 seen in the control group (Table 1) , indicating that the small percentage of mice treated with 4 mM AACOCF 3 that got EAE showed a remarkably milder form of the disease. Unlike the controls, which relapsed into a second paralytic episode between days 25 and 34, mice treated with 4 mM AACOCF 3 remained largely unaffected ( Figure 3 , Table 1 ). The treatment is well tolerated in that the animals did not show any observable side effects. These data suggest that the inhibitor treatment is well tolerated and can prevent disease when given before symptoms occur.
To examine the effects of the inhibitor treatment at the protein level, we first assessed the expression of cPLA 2 and one of the downstream enzymes, COX-2, in the spinal cords of untreated EAE mice that reached a clinical score of grade 3 on day 13; mice treated with AACOCF 3 that were also sacrificed on day 13 in which the disease was prevented; and normal healthy control mice. Cytosolic PLA 2 , seen as an 85 kDa band on Western blots, was elevated in untreated EAE mice as compared to normal controls ( Figure 4A ). COX-2, a 72 kDa receptors were increased Ͼ2-fold in mice in the un-1993). It is about 500-fold more potent at inhibiting treated EAE group as compared to normal controls (TacPLA 2 than sPLA 2 (Street et al., 1993). It may also be a bles 2 and 3). In the cPLA 2 inhibitor-treated mice, the weak inhibitor of the calcium-independent form of PLA 2 expression of 80% of these genes returned to normal (Riendeau et al., 1994; Ackermann et al., 1995; Gholevels, while 14% were reduced but still remained higher mashchi et al., 1999). Arachidonyl analogs have been than in normal controls (these include CCR5, CXCR4, shown to be relatively nontoxic to cells (Riendeau et al., CCL19/MIP-3␤, Dfy, and angiopoietin 2), and 6% were 1994). C57BL/6 mice were treated with AACOCF 3 on the similar to the EAE levels (CXCL12/SDF-1 and CX 3 CL1/ day of induction of EAE and on day 2 with 50 l of 2 or fractalkine) ( Figures 4C and 4D) . Many of the chemokine/ 4 mM AACOCF 3 intravenously, followed by intraperitochemokine receptor and cytokine genes that were eleneal injections of the inhibitor (200 l at 2 or 4 mM) on vated in untreated EAE mice are those that have already alternate days until day 24. Treatment with the inhibitor been implicated in the pathogenesis of EAE ( new candidates in EAE pathology (Table 3) Table  4 ), the maximum period studied. Their progression into a second relapse was prevented. In contrast, their matching untreated controls, which also remitted to a clinical score of grade 2 or below on day 14 and which had initially peaked to a mean grade of 3.2, progressed into a second paralytic episode (grade 2.9) between days 25 and 37. These mice, which display a relapsingremitting form of the disease, remained thereafter at a Figures 6D-6H ). This axonal the CNS. The expression of cPLA 2 in T cells and macroloss may account for the permanent clinical deficits seen phages could play a role in recruitment of additional in these groups. In contrast to these chronic groups, immune cells, leading to further progression of the disthe control group with the relapsing-remitting course ease at later stages. We also demonstrate that by (mean clinical score of 1.8 on day 60) showed fewer blocking the activity of cPLA 2 using a chemical inhibitor damaged axons, while the companion treated group, of this enzyme, the disease incidence can be drastically which improved with treatment (mean clinical score of curtailed and the disease severity markedly reduced 0.3 on day 60), showed virtually no damaged axons (data when treatment is initiated at the time of induction of not shown). These data indicate that the failure of mice EAE. This reduction in disease severity correlates with with the more severe form of EAE to improve with the a decrease in cPLA 2 and its downstream mediators such inhibitor treatment may be due to permanent axonal as COX-2, LTB 4 R2, and various chemokines and cytodamage.
kines that contribute to the inflammatory and neural pathology in EAE. Furthermore, we show that inhibiting cPLA 2 after the disease is full-blown has a remarkable Discussion effect in reducing inflammation, axonal damage, and the clinical severity and preventing further remissions Our data indicate an important role for cPLA 2 in the in animals showing a relapsing-remitting form of the pathogenesis of EAE, the animal model of MS. We demonstrate an increased expression of cPLA 2 in endothelial disease. postfixed in 2% osmium tetroxide and processed and embedded between the various grades was determined by using a two-sample in Epon as described previously (Ousman and David, 2000) . Thin Student's t test.
One of the major pathologies in MS and EAE is a after onset of EAE as compared to COX inhibitor treatment (Traugott and
sections on Collodion-coated slot grids were stained with lead citrate and examined with a Philips CM10 electron microscope. Treatment of EAE EAE was induced in C57BL/6 mice as mentioned above. Mice were
